A Phase III, 12-Month, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety (Including Bone Density Assessment) of Two Doses of J867 [asoprisnil] Versus Placebo in Subjects With Uterine Leiomyomata [uterine leiomyoma]

Trial Profile

A Phase III, 12-Month, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety (Including Bone Density Assessment) of Two Doses of J867 [asoprisnil] Versus Placebo in Subjects With Uterine Leiomyomata [uterine leiomyoma]

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2008

At a glance

  • Drugs Asoprisnil (Primary)
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Sponsors TAP Pharmaceutical Products
  • Most Recent Events

    • 24 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top